Paudel Anish, Basnet Sijan, Tharu Biswaraj, Bohra Nidrit
Department of Medicine, Reading Hospital, West Reading, Pennsylvania.
Department of Medicine, Trumbull Regional Medical Center, Warren, Ohio.
Proc (Bayl Univ Med Cent). 2020 Aug 19;34(1):81-82. doi: 10.1080/08998280.2020.1805672.
Diffuse exanthematous drug eruption due to intravenous immunoglobulin (IVIg) is a rare adverse event reported only in case reports. We present a case of a 71-year-old woman with a diffuse maculopapular rash 5 days after receiving an IVIg infusion for treatment of chronic inflammatory demyelinating polyneuropathy. She was managed conservatively with antihistamines; she was already receiving prednisone 25 mg daily as part of treatment for the neuropathy. The rash resolved over 2 weeks.
静脉注射免疫球蛋白(IVIg)引起的弥漫性疹性药疹是一种仅在病例报告中出现的罕见不良事件。我们报告一例71岁女性患者,在接受IVIg输注治疗慢性炎症性脱髓鞘性多发性神经病5天后出现弥漫性斑丘疹。她接受了抗组胺药的保守治疗;作为神经病治疗的一部分,她已经在每日服用25毫克泼尼松。皮疹在2周内消退。